meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">non platinum-based chemotherapy</span>
<span style="margin-left: 2em;">taxanes</span>
<span style="margin-left: 3em;">docetaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">nivolumab based treatment</span>
<span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
AE (any grade) (2)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
STRAE (any grade) (1)
STRAE (grade 3-4) (1)
Neutropenia TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Vomiting TRAE (grade 3-4) (1)
Hyperthyroidism TRAE (grade 3-4) (1)
Thyroiditis TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Colitis TRAE (grade 3-4) (1)
Increased ALT TRAE (grade 3-4) (1)
Increase AST TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Arthralgia TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Maculopapular rash TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Pyrexia TRAE (grade 3-4) (1)
Pruritic rash TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Constipation TRAE (grade 3-4) (1)
Paraesthesia TRAE (grade 3-4) (1)
Leucopenia TRAE (grade 3-4) (1)
Alopecia TRAE (grade 3-4) (1)
Myalgia TRAE (grade 3-4) (1)
Hypersensitivity TRAE (grade 3-4) (1)
Diabetes TRAE (grade 3-4) (1)
Peripheral neuropathy TRAE (grade 3-4) (1)
Peripheral oedema TRAE (grade 3-4) (1)
Mucosal inflammation TRAE (grade 3-4) (1)
Dysgeusia TRAE (grade 3-4) (1)
Stomatitis TRAE (grade 3-4) (1)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (1)
Erythema TRAE (grade 3-4) (1)
Urticaria TRAE (grade 3-4) (1)
Skin exfoliation TRAE (grade 3-4) (1)
Eczema TRAE (grade 3-4) (1)
Acute kidney injury TRAE (grade 3-4) (1)
Blood creatinine increased TRAE (grade 3-4) (1)
Pruritus generalised TRAE (grade 3-4) (1)
Infusion-related reactions TRAE (grade 3-4) (1)
Febrile neutropenia TRAE (grade 3-4) (1)
Increased lacrimation (TRAE grade 3-4) (1)
Constipation AE (grade 3-4) (1)
Abdominal pain AE (grade 3-4) (1)
Fatigue AE (grade 3-4) (1)
Asthenia AE (grade 3-4) (1)
Headache AE (grade 3-4) (1)
Decreased appetite AE (grade 3-4) (1)
Dyspnoea AE (grade 3-4) (1)
Cough AE (grade 3-4) (1)
Increased ALT AE (grade 3-4) (1)
Diarrhoea AE (grade 3-4) (1)
Rash AE (grade 3-4) (1)
Pyrexia AE (grade 3-4) (1)
Weight decreased AE (grade 3-4) (1)
Pruritus AE (grade 3-4) (1)
Back pain AE (grade 3-4) (1)
Hypothyroidism AE (grade 3-4) (1)
Arthralgia AE (grade 3-4) (1)
Stomatitis AE (grade 3-4) (1)
Mucosal inflammation AE (grade 3-4) (1)
Dysgeusia AE (grade 3-4) (1)
Anaemia AE (grade 3-4) (1)
Neutropenia AE (grade 3-4) (1)
Dizziness AE (grade 3-4) (1)
Oropharyngeal pain AE (grade 3-4) (1)
Dry skin AE (grade 3-4) (1)
Peripheral oedema AE (grade 3-4) (1)
Nausea AE (grade 3-4) (1)
Febrile neutropenia AE (grade 3-4) (1)
Leucopenia AE (grade 3-4) (1)
Peripheral neuropathy AE (grade 3-4) (1)
Myalgia AE (grade 3-4) (1)
Alopecia AE (grade 3-4) (1)
Paraesthesia AE (grade 3-4) (1)
Erythema AE (grade 3-4) (1)
Pneumonia AE (grade 3-4) (1)
Vomiting AE (grade 3-4) (1)
Lacrimation increased AE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
CheckMate 057, 2015
docetaxel
nivolumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
docetaxel
nivolumab alone
docetaxel
---
NA
nivolumab alone
NA
---
pathologies: 279,167,1,170,261 - treatments: 360,719,721,720
result logic
×
Study list
